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Abstract: Objective: To investigate the effects of intravitreal bevacizumab (IVB) injection before
PRP on the prevention of macular edema (ME) in patients with PDR. Methods: This retrospective
observational study included patients diagnosed with PDR treated by PRP with (combination group)
or without (PRP alone group) preoperative IVB injection (1.25 mg/0.05 mL). The primary outcome
measure was the change in the central macular thickness (CMT), while the secondary outcome
measure was the change in visual acuity. Measurements were made before and at one, two, and three
months after treatment. Results: In the PRP alone group, the mean baseline CMT of 277.8 µm
increased to 290.4 µm at one month (p = 0.201) and 308.8 µm at two months (p = 0.002), followed by a
decrease to 271.2 µm at three months (p = 0.437). In the combination group, the values at baseline
and one, two, and three months after PRP were 322.9 µm, 295.4 µm (p = 0.002), 330.1 µm (p = 0.906),
and 274.5 µm (p = 0.030), respectively. Visual acuity changes were comparable between the two
groups at all time points. Conclusion: IVB injection before PRP leads to decreased CMT in comparison
to CMT in patients with PRP alone.
Keywords: proliferative diabetic retinopathy; central macular thickness; panretinal photocoagulation;
intravitreal bevacizumab; macular edema
1. Introduction
Diabetic retinopathy (DR) is one of the leading causes of vision loss in developed countries [1,2].
Studies have shown that macular edema (ME) and retinal neovascularization (NV) are among the
most significant factors mediating vision loss in patients with DR [1–3]. The Diabetic Retinopathy
Study demonstrated that, compared to no treatment, laser photocoagulation treatment resulted in a
50% improvement in visual retention in patients with high-risk proliferative DR (PDR) [4]. Since then,
panretinal photocoagulation (PRP) has become the standard treatment for PDR. However, PRP can
increase the risk of ME, vitreous hemorrhage, retinal atrophy, burn enlargement, choroidal NV (CNV),
and visual field decrease [5–7]. Previous studies have shown that 25–43% of eyes treated with PRP
develop ME and visual disturbances [5–7]. While the exact mechanism underlying ME development
after PRP has not been determined, studies have suggested that the release of inflammatory factors
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after laser irradiation leads to the accumulation of leukocytes, upregulation of angiogenic growth
factors such as vascular endothelial growth factor (VEGF), and edematous changes in the retina [8,9].
VEGF induces the formation of abnormal capillaries and consequently plays an important role in
the pathogenesis of PDR [10]. Anti-VEGF agents can cause PDR regression and hasten the resolution
of diabetic vitreous hemorrhage [11,12]. Several clinical trials have also reported good outcomes of
anti-VEGF treatment for ME and retinal NV in patients with diabetes [13,14].
Among the widely used anti-VEGF agents, bevacizumab is a well-known recombinant humanized
monoclonal antibody that blocks angiogenesis by inhibiting VEGF-A. It has been successfully used
for alleviating ME and NV in patients with PDR [15]. Both PRP and intravitreal bevacizumab (IVB)
injection can be useful for PDR treatment, and the effects of bevacizumab and PRP combination therapy
have been evaluated in several studies [6,16,17]. However, these studies involved intravitreal injections
after PRP. To date, only a few studies have focused on the efficacy of intravitreal anti-VEGF injections
before PRP, with conflicting results [17–19].
We hypothesized that IVB injection before PRP can prevent the development of ME in patients with
PDR. Accordingly, the aim of the present study was to compare the effects of PRP with preoperative
IVB injection with those of PRP alone on the prevention of ME in patients with PDR.
2. Experimental Section
2.1. Patient Enrollment
This study was designed as a retrospective, observational, single-center study. All procedures
involving human participants were in accordance with the ethical standards of the institutional
and/or national research committee, and with the 1964 Helsinki declaration and its later amendments,
or comparable ethical standards. Data for patients with PDR who received PRP between January
2014 and March 2016 were retrospectively reviewed. A systematic evaluation of medical records was
performed, and data pertaining to medical history, blood pressure, serum glycosylated hemoglobin
(HbA1c) levels, and the findings of complete ocular examinations were reviewed. Ocular examinations
included visual acuity measurements (logarithm of the minimum angle of resolution (logMAR)),
intraocular pressure measurements, fundus examinations, and CMT measurements performed using
spectral domain (SD) optical coherence tomography (OCT) with the Heidelberg OCT device (Heidelberg
Engineering, Heidelberg, Germany). Multiple linear scans were processed for obtaining a retinal
thickness map. The CMT value reported in the CMT map represented the mean retinal thickness of
the macula.
The inclusion criteria were PDR patients with evidence of neovascularization documented on
fluorescein angiography. PDR was defined as neovascularization arising from the optic disc and/or
retina, which may cause preretinal and vitreous hemorrhage. The exclusion criteria were as follows:
lack of preoperative or postoperative OCT findings; history of intraocular surgeries between PRP and
IVB injection; severe vitreous hemorrhage; macular hole; epiretinal membrane; active external eye
infection; history of thromboembolic events, including myocardial infarction and stroke; systolic and
diastolic blood pressures of > 180 and > 110 mmHg, respectively; HbA1c levels of > 15%; visual acuity
under 20/200; and history of major surgery within the last month. Patients with clinically significant
lens opacity that may affect vision were also excluded from the study.
2.2. Study Design
In total, data for 498 patients were retrospectively reviewed. The selected eyes were divided into
a combination group, which included those who received IVB injection (1.25 mg/0.05 mL; Avastin®,
Genentech Inc., San Francisco, CA, USA) before PRP, and a PRP alone group, which included those
treated with PRP without IVB injection. The eyes in the combination group received IVB injection one
to four weeks before PRP. The criteria for group allocation were decided by the retinal specialist that
treated the patients. Visual acuity, intraocular pressure measurements, and fundus examinations were
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performed before and at one, two, and three months after PRP. Injection-related complications, such as
an increase in the intraocular pressure and progression of cataract, were also reviewed.
Approval for this study was obtained from the Gangnam Severance Hospital Institutional Review
Board, which provided a waiver of informed consent for the retrospective review of existing patient
records (IRB number: 3-2016-0227). The methods adhered to the tenets of the Declaration of Helsinki
and were HIPAA compliant.
2.3. Intravitreal Injection Procedure
An eyelid speculum was used to stabilize the eyelids. Each eye was prepared using 5% povidone
iodine. Bevacizumab (Genentech Inc., South San Francisco, CA, USA) was injected 3.5 mm posterior to
the corneal limbus through the pars plana.
2.4. OCT Measurements
All eyes underwent OCT before and after treatment at Yonsei University Medical Center,
Seoul, Korea. Images of the macula were obtained using an SD-OCT device (Spectralis OCT,
Heidelberg Engineering, Franklin, MA, USA). Independent observers performed all measurements.
Central thickness maps derived from pre- and post-treatment OCT images were used for
CMT calculation.
ME was defined as an accumulation of fluid in the retinal layers around the fovea, resulting
in an increased thickening of the retina. Central macular thickness of >300 µm shown in the OCT
examination was considered to indicate ME [20].
2.5. PRP Procedure
PRP was performed under topical anesthesia with 0.5% proxymetacaine hydrochloride eye drops.
A 532 nm green light laser (PASCAL®, Topcon Medical Laser Systems, Inc. Santa Clara, CA, USA) with
a Mainster Wide Field lens was used for PRP. The inferior and superior areas of the retina were treated
in the first and second sessions, respectively. Usually, two sessions were performed in each eye, and a
two-week period was maintained between the sessions. OCT was performed after two sessions were
completed. Topical anesthetics were used at the time of performing PRP. The spot size was 200 µm,
the exposure time was approximately 0.2 s, and the power was adjusted such that a gray–white lesion
was produced. Approximately 600–700 laser spots were placed in each session.
2.6. Statistical Analysis
All data were statistically analyzed using SPSS 21.0 software (SPSS, Chicago, IL, USA).
The values are expressed as means ± standard deviations. Differences between groups were
examined by independent t-tests or Wilcoxon signed rank tests. A p-value of < 0.05 was considered
statistically significant.
3. Results
Of the 498 patients who underwent PRP treatment for PDR, 74 (93 eyes) were considered eligible
for our retrospective review. Of the 93 eyes, 55 were included in the PRP alone group and 38 in the
combination group (Figure 1). The two groups showed no significant differences in demographic and
baseline ocular characteristics except the mean CMT (Table 1). The mean age of participants was 58.7
and 56.6 years in the PRP alone and combination groups, respectively. The mean logMAR visual acuity
was 0.246 and 0.311, respectively, while the mean CMT was 277.8 (range = 223 to 353 µm) and 322.9 µm
(range = 234 to 652 µm), respectively. In the PRP alone group, there were 15 eyes with ME at baseline.
In the combination group, 19 eyes exhibited baseline ME. When the eyes without baseline ME were
considered, the mean CMT was 260.3 µm (range = 223 to 296 µm) in the PRP alone group (n = 40) and
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256.6 µm (range = 234 to 288 µm) in the combination group (n = 19), with no significant difference in
the logMAR visual acuity (0.262 and 0.226, respectively; p = 0.627; Table 1).
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group was further classified according to the presence of ME at baseline. IVB: intravitreal 
bevacizumab, ME: macular edema, PRP: panretinal laser photocoagulation, PDR: proliferative 
diabetic retinopathy. 
Table 1. Baseline clinical characteristics of patients with proliferative diabetic retinopathy who 
underwent panretinal photocoagulation with (combination group) or without (PRP only group) 
preoperative intravitreal bevacizumab injection (1.25 mg/0.05 mL). 
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58.9 (6.78) 57.3 (8.48) 58.7 (7.27) 56.8 (16.71) 54.9 (13.29) 56.6 (14.35) 0.550/0.569/0.436 
HbA1c 8.18 7.33 7.78 8.44 6.83 8.14 0.739/0.430/0.704 
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(mmHg) 
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0.262 0.197 0.246 0.226 0.408 0.311 0.627/0.335/0.319 
ME: macular edema, PRP: panretinal laser photocoagulation, PDR: proliferative diabetic retinopathy, 
BP: blood pressure, CMT: central macular thickness, HbA1c: glycosylated hemoglobin, V/A: visual 
acuity, SD: standard deviation; comparisons were performed using t-tests. 
3.1. Overall Changes in CMT in the Two Groups (PRP Alone: n = 55, Combination: n = 38) 
In the PRP alone group, the mean CMT exhibited a significant increase at two months after PRP. 
On the other hand, the mean CMT in the combination group exhibited a significant decrease at both 
one and three months after PRP. In the PRP alone group, the mean CMT increased from 277.8 μm at 
baseline to 290.4 μm at one month (p = 0.201) and 308.8 μm at two months (p = 0.002), followed by a 
Figure 1. Patient enrollment and study design. In total, 93 eyes of 74 patients with PDR were enrolled. Of
these, 55 eyes underwent only PRP and 38 underwent PRP with preoperative IVB injection. Each group
was further classified according to the presence of ME at baseline. IVB: intravitreal bevacizumab, ME:
macular edema, PRP: panretinal laser photocoagulation, PDR: proliferative diabetic retinopathy.
Table 1. Baseline clinical characteristics of patients with proliferative diabetic retinopathy who
underwent panretinal photocoagulation with (combination group) or without (PRP only group)
preoperative intravitreal bevacizumab injection (1.25 mg/0.05 mL).
Characteristics PRP Only Group Combination Group p-Value
Presence of ME




patien s 30 11 41 15 18 33
Number of eyes 40 15 55 19 19 38
Sex
(Male/Female) 13/15 10/3 23/18 7/8 14/4 21/12
Age, mean (SD)
years 58.9 (6.78) 57.3 (8.48) 58.7 (7.27) 56.8 (16.71) 54.9 (13.29) 56.6 (14.35) 0.550/0.569/0.436
HbA1c 8.18 7.33 7.78 8.44 6.83 8.14 0.739/0.430/0.704
BP systolic
(mmHg) 140 135 138 128 133 131 0.095/0.452/0.261
BP diastolic
(mmHg) 79 82 80 81 74 78 0.501/0.109/0.146
Mean baseline




0.262 0.197 0.246 0.226 0.408 0.311 0.627/0.335/0.319
ME: macular edema, PRP: panretinal laser photocoagulation, PDR: proliferative diabetic retinopathy, BP: blood
pressure, CMT: central macular thickness, HbA1c: glycosylated hemoglobin, V/A: visual acuity, SD: standard
deviatio ; comparisons were performed using t-tests.
3.1. Overall Changes in CMT in the Two Groups (PRP Alone: n = 55, Combination: n = 38)
In the PRP alone group, the mean CMT exhibited a significant increase at two months after PRP.
On the other hand, the mean CMT in the combination group exhibited a significant decrease at both
one and three months after PRP. In the PRP alone group, the mean CMT increased from 277.8 µm
at baseline to 290.4 µm at one month (p = 0.201) and 308.8 µm at two months (p = 0.002), followed
by a decrease to 271.2 µm at three months (p = 0.437). In the combination group, the mean CMT
was 322.9 µm at baseline, 295.4 µm at one month (p = 0.002), 330.1 µm at two months (p = 0.906),
and 274.5 µm at thre m nths (p = 0.030; Figure 2A).
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Figure 2. Changes in CMT in patients with PDR who received PRP with or without preoperative IVB 
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two, and three months after PRP (** p < 0.05). (A) Overall changes in CMT in the two groups. (B) Changes 
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Figure 2. Changes in CMT in patients with PDR who received PRP with or without preoperative IVB
injection. The mean CMT was measured using central thickness mapping with OCT at baseline and
one, two, and three months after PRP (* p < 0.05, ** p < 0.01). (A) Overall changes in CMT in the
two groups. (B) Changes in CMT in patients without baseline ME in both groups. (C) Changes in
CMT in patients with baseline ME in both groups. IVB: intravitreal bevacizumab, PRP: panretinal
laser photocoagulation, PDR: proliferative diabetic retinopathy, CMT: central macular thickness, OCT:
optical coherence tomography, ME: macular edema.
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3.2. Changes in CMT in the Eyes Without Baseline ME in the Two Groups (PRP Alone: n = 40, Combination:
n = 19)
With regard to the eyes without ME at baseline, there was no significant difference in the mean
baseline CMT between the PRP alone and combination groups (260.3 µm and 256.6 µm, respectively;
p = 0.509). In the PRP alone group, the mean CMT significantly increased at two months after PRP.
In contrast, the mean CMT in the combination group showed no significant changes during the
follow-up period. In the PRP alone group, the mean CMT at baseline and one, two, and three months
after PRP was 260.3, 267.0 (p = 0.080), 281.8 (p = 0.024), and 261.9 (p = 0.778) µm, respectively; these
values were 266.1, 255.4 (p = 0.162), 269.0 (p = 0.960), and 263.8 (p = 0.055) µm, respectively, in the
combination group (Figure 2B).
3.3. Changes in CMT in Eyes with Baseline ME in the Two Groups (PRP Alone: n = 15, Combination: n = 19)
The mean CMT in eyes with baseline ME exhibited a significant increase at one month
after PRP in the PRP alone group and a significant decrease at one month after PRP in the
combination group. In the PRP alone group, the mean CMT was 323.3 µm at baseline and 350.0
(p = 0.031), 345.9 (p = 0.107), and 327.0 (p = 0.750) µm at one, two, and three months after PRP,
respectively. In the combination group, these values were 386.2, 341.7 (p = 0.009), 353.9 (p = 0.956),
and 339.0 (p = 0.926; Figure 2C) µm, respectively.
3.4. Changes in Visual Acuity
Visual acuity changes at all time points were comparable between the PRP alone and combination
groups, regardless of the presence of baseline ME. Although there were no statistically significant
differences, all groups showed the same trend of a decrease during the first month after treatment and
recovery thereafter (Figure 3).
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Figure 3. Visual acuity changes in patients with PDR who received PRP with or without preoperative
IVB injection. Visual acuity was measured at baseline and one, two, and three months after PRP.
(A) Overall changes in the logMAR visual acuity in the two groups. (B) Changes in the logMAR visual
acuity in patients without baseline ME in both groups. (C) Changes in the logMAR visual acuity
in patients with baseline ME in both groups. IVB: intravitreal bevacizumab, PRP: panretinal laser
photocoagulation, PDR: proliferative diabetic retinopathy, logMAR: logarithm of the minimum angle
of resolution, ME: macular edema.
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3.5. Injection-Related Complications
No significant adverse events were recorded during the follow-up period. None of the eyes
showed significant cataract progression or endophthalmitis during the follow-up period. Moreover,
there were no statistically significant differences in the follow-up intraocular pressure measurements
between the two groups (data not shown). No systemic adverse events were recorded for any patient.
4. Discussion
In the present study, we found that IVB injection before PRP prevented ME development and
even reduced existing ME in patients with PDR.
Currently, PRP is one of the most important treatment modalities for PDR. The Early Treatment
Diabetic Retinopathy Study reported that early photocoagulation lowers the risk of severe vision
loss after five years by 23% [3]. While PRP can salvage the patient’s vision, it is associated with side
effects, such as the development of ME [5–7]. In the present study, CMT increased when PRP was
performed alone and decreased when PRP was preceded by IVB injection. ME induced by PRP was
also observed, consistent with findings in previous reports [6,7,21]. Interestingly, IVB injection before
PRP was also found to reduce existing ME up to three months after PRP. Moreover, bevacizumab
injection is relatively cheaper than aflibercept or ranibizumab injections [22,23]. Thus, adjunctive
bevacizumab injection before PRP can serve as a good, cost-effective treatment.
We also found that our results were influenced by the presence of ME before PRP. For eyes
without baseline ME, CMT during the follow-up period remained similar in the combination group and
increased in the PRP alone group. On the other hand, when ME was present at baseline, combination
treatment led to a significant decrease in CMT. Thus, IVB injection can be used before PRP even if ME
is present at baseline, considering it showed the ability to not only prevent the development of ME,
but also treat existing ME.
The effects of IVB injection before PRP observed in the present study can be attributed to several
reasons. Even though PRP is an established therapy for the regression of NV, several studies have
observed negative effects on retinal structure and function [24,25]. During PRP, the retinal pigment
epithelium is the principal site for laser energy absorption, and the subsequent damage spreads to the
retina. After PRP treatment, cytokines, such as VEGF, interleukin-6 (IL-6), and RANTES (CCL5), are
upregulated. These cytokines may be the primary contributors to ME immediately after PRP [26–29].
VEGF plays an important role in the breakdown of the blood–retinal barrier. This breakdown leads to an
increase in vascular permeability and fluid leakage, eventually resulting in the development of ME [30].
VEGF also induces vessel dilation and increases the ocular blood flow. Therefore, inhibition of VEGF
by bevacizumab may reduce the retinal vascular permeability and decrease fluid leakage. Although
VEGF decreases over time after PRP, it does not decrease immediately after the procedure [27,31].
This may have attributed to the favorable effects of preoperative IVB injection in our study. In the
group with ME at baseline, IVB may have reduced the existing ME via its anti-VEGF effects in the
early phase, which overwhelm the effects of other cytokines. Alternatively, IVB may have offset the
newly developing ME in the group without ME at baseline. Unlike CMT, however, we did not find a
significant difference in visual acuity changes after treatment between the two groups. This may be
due to the small sample size or the short follow-up period.
This study had some limitations, including the retrospective design, relatively small sample size,
short-term follow-up period, and the fact that the baseline CMT was different between the combination
and PRP only groups. However, when the eyes were classified according to the presence or absence of
ME at baseline, those with similar CMT and the absence of ME at baseline still demonstrated favorable
outcomes after PRP with preoperative IVB injection. Additionally, the fact that the exact time for IVB
injection was not the same (IVB injection was performed one to four weeks before PRP) and that the
study included patients with poor glycemic control may have affected the study results. Hence, large,
randomized prospective studies are necessary to overcome these limitations and confirm our results.
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Moreover, further studies should determine the optimal timing for IVB injection before PRP, because
no studies have assessed this parameter to date.
In summary, we found that IVB injection before PRP leads to decreased CMT in comparison to
CMT in patients with PRP alone. These findings suggest that IVB injection prior to PRP may be an
effective adjunctive modality for the prevention of ME after PRP or the treatment of existing ME in
patients with PDR.
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